Company / Current Liabilities
Larimar Therapeutics, Inc. Current Liabilities History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$12.2M
FY2019
5-year range
$7.3M / $16.5M
FY2015-FY2019
Trend
-8.4%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 6 years, ranging from $7M in FY2014 to $17M in FY2015.
Based on SEC 10-K filings.
$12M in FY2019 with a 5-year CAGR of +12.1%.
Increased from $7M to $12M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- +12.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +12.1%, indicating consistent growth.
- In FY2019, current liabilities decreased 8.4% year-over-year.
- Peak current liabilities was recorded in FY2015.
- Lowest current liabilities in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $12.2M | -8.4% |
| FY2018 | $13.3M | +82.4% |
| FY2017 | $7.3M | -26.3% |
| FY2016 | $9.9M | -40.2% |
| FY2015 | $16.5M | +139.7% |
| FY2014 | $6.9M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026